Yogi Berra, an exceptionally gifted baseball player, was a font of wisdom. One of his most famous quotes, “When you come to a fork in the road, take it,” applies to the conundrum tackled by Paone et al in this volume of The Journal. Approximately 43% of infants and 10% of older children with congenital hypothyroidism have elevated levels of both thyrotropin (TSH) and thyroxine (T4). When both T4 and triiodothyronine (T3) are elevated, pediatricians are in the untenable position of having to determine if they should overtreat in an attempt to normalize the TSH at the possible expense of increasing the T4 above normal, when studies have demonstrated impaired school performance, lower IQ, and a higher risk of attention deficit in children who had high T4 concentrations in infancy (J Pediatr 2000;136:292-7; Pediatrics 2003;112:923-30). Or, should they attempt to maintain normal T4 values while TSH concentrations remain mildly elevated? Although the evidence that low T4 levels during the time of rapid brain growth affects intellectual functioning, the evidence that elevated TSH values during the first 3 years of life is less robust, though one study reported poorer school performance in children who had TSH elevations in infancy (Acta Paediatr 2001;90:1249-56). Due to the lack of data, we do not know which fork to take in this particular road. The cause of the abnormal lack of suppression of TSH with adequate levothyroxine administration is unknown. Affected infants might have abnormally low thyroid gland secretion of T3, abnormally low conversion of T4 to T3, or abnormal central feedback with lack of normal TSH suppression (ie, central resistance to thyroid hormone). Paone et al hypothesized that the lack of suppression of TSH by appropriate doses of levothyroxine (LT4) could be overcome with the addition of liothyroninie (LT3), as shown in other studies (Horm Res Paediatr 2010;73:108-14; J Pediatr Endocrinol Metab 2011;24:347-50). In order to assess this hypothesis, the authors performed a retrospective analysis of clinical data of 12 patients with CH with both high T4 and TSH values. Six of them had been treated with LT4 alone followed by LT4 + LT3 and 6 only received LT4. The addition of LT3 resulted in the normalization of TSH (mean 4.3 mIU/L, down from 10 mIU/L pre-T3 treatment , vs 8.5 mIU/L in the T4 monotherapy group). The T4 values were likewise normalized, with a mean decrease of 23% ± 9% from pretreatment values. T3 concentrations remained normal for age. Because this was a retrospective study, the groups were neither matched for the age of treatment initiation nor given a neurodevelopmental assessment. However, this is a promising treatment for infants with persistent elevation of TSH and T4 despite appropriate treatment with levothyroxine. Long-term randomized controlled trials are needed to assess the effect of this regimen on thyroid hormone values. But, the real question that must be answered is not whether the laboratory values can be normalized but whether this regimen can improve neurocognitive functioning in these children, including not only intelligence but also school performance. And, hopefully, this study will help us to determine which fork in this particular road we should take. Article page 167▶ Liothyronine Improves Biochemical Control of Congenital Hypothyroidism in Patients with Central Resistance to Thyroid HormoneThe Journal of PediatricsVol. 175PreviewTo assess whether adding liothyronine (LT3) to levothyroxine (LT4) monotherapy normalizes serum thyrotropin (TSH) and thyroxine (T4) concentrations in children with congenital hypothyroidism and central resistance to thyroid hormone. Full-Text PDF